Literature DB >> 1706453

Characterization of pathological dystrophin transcripts from the lymphocytes of a muscular dystrophy carrier.

M Schloesser1, R Slomski, M Wagner, J Reiss, L P Berg, V V Kakkar, D N Cooper.   

Abstract

Both normal and pathological transcripts of tissue-specific genes may be detected by polymerase chain reaction (PCR) amplification in tissues not normally considered to express the gene product. The exploitation of constitutive basal mRNA levels ("ectopic" transcription) would be a major boon to diagnostic medicine since it promises both to simplify the analysis of complex genes and to avoid the requirement for an expressing tissue that is sometimes obtainable only by biopsy. We have demonstrated the feasibility of this novel strategy by characterizing a mutation in the X-chromosomal Duchenne (or Becker) muscular dystrophy (DMD/BMD) gene encoding dystrophin. The massive size of this gene has in the past often hindered carrier detection due to the high frequency of recombination and the high proportion of new mutations. In this study a deletion was identified in both a BMD patient and a heterozygous carrier using only a minimal volume of peripheral blood. Following specifically primed reverse transcription of lymphocyte RNA, the relevant region of the pathological cDNA was PCR-amplified. Sequence analysis indicated an in-frame deletion of exons 45 to 47.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1706453

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  10 in total

1.  The mutational spectrum of single base-pair substitutions in mRNA splice junctions of human genes: causes and consequences.

Authors:  M Krawczak; J Reiss; D N Cooper
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

2.  Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.

Authors:  P Burfeind; C L Chernicky; F Rininsland; J Ilan; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Detection of human spermatid-specific transcripts in peripheral blood lymphocytes of males and females.

Authors:  R Slomski; M Schloesser; H Chlebowska; J Reiss; W Engel
Journal:  Hum Genet       Date:  1991-07       Impact factor: 4.132

4.  A novel 5'-upstream mutation in the factor XII gene is associated with a TaqI restriction site in an Alu repeat in factor XII-deficient patients.

Authors:  S Hofferbert; J Müller; H Köstering; W D von Ohlen; M Schloesser
Journal:  Hum Genet       Date:  1996-06       Impact factor: 4.132

5.  Brain- and muscle-type promoters of the dystrophin gene are selected in peripheral lymphocytes and Epstein Barr virus-transformed lymphoblastoid [correction of lymphoplastoid] cells.

Authors:  H Nishio; M Matsuo; Y Kitoh; N Narita; M Shimmoto; Y Suzuki; H Nakamura
Journal:  J Neurol       Date:  1993-12       Impact factor: 4.849

6.  Identification of a new DMD gene deletion by ectopic transcript analysis.

Authors:  F Rininsland; A Hahn; S Niemann-Seyde; R Slomski; F Hanefeld; J Reiss
Journal:  J Med Genet       Date:  1992-09       Impact factor: 6.318

7.  Omission of exon 12 in cystic fibrosis transmembrane conductance regulator (CFTR) gene transcripts.

Authors:  R Slomski; M Schloesser; L P Berg; M Wagner; V V Kakkar; D N Cooper; J Reiss
Journal:  Hum Genet       Date:  1992-08       Impact factor: 4.132

8.  Alternative splicing of dystrophin mRNA complicates carrier determination: report of a DMD family.

Authors:  U Lenk; S Demuth; U Kräft; R Hanke; A Speer
Journal:  J Med Genet       Date:  1993-03       Impact factor: 6.318

9.  Molecular genetic analysis of 67 patients with Duchenne/Becker muscular dystrophy.

Authors:  S Niemann-Seyde; R Slomski; F Rininsland; U Ellermeyer; J Kwiatkowska; J Reiss
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

10.  Illegitimate transcription. Application to the analysis of truncated transcripts of the dystrophin gene in nonmuscle cultured cells from Duchenne and Becker patients.

Authors:  J Chelly; H Gilgenkrantz; J P Hugnot; G Hamard; M Lambert; D Récan; S Akli; M Cometto; A Kahn; J C Kaplan
Journal:  J Clin Invest       Date:  1991-10       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.